Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Impel Neuropharma is raising $1,578,736.00 in a new round of investment. Sources indicate as part of senior management President and Chief Executive Officer, Jon Congleton played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Impel Neuropharma

Impel NeuroPharma is developing transformative therapies for people suffering from central nervous system disorders with high unmet medical needs. We are developing therapies that have the potential to deliver injection-like clinical outcomes via our proprietary formulations and upper nasal delivery technology.

To learn more about Impel Neuropharma, visit http://www.impelneuropharma.com/

Contact:
Jon Congleton, President and Chief Executive Officer
206-568-1466
congleton@impelneuropharma.com
https://www.linkedin.com/in/joncongleton/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved